Navigation Links
S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
Date:12/1/2008

SINGAPORE, Dec. 1 /PRNewswire/ -- S*BIO Pte Ltd today announced the initiation of a Phase 1/2 clinical trial of SB1518, a potent and orally-active JAK2 inhibitor, in leading medical centers in Australia for patients with chronic idiopathic myelofibrosis (CIMF).

The trial is designed to evaluate the safety and tolerability of SB1518 in patients with CIMF and is expected to enrol up to 50 patients. The Phase 1 part of the study will assess the safety profile and evaluate the pharmacokinetic and pharmacodynamic activities of SB1518, and the Phase 2 component will assess the clinical benefits and continue to evaluate the safety profile of SB1518. The principal investigators are Dr. Andrew Roberts at the Royal Melbourne Hospital and Dr. John Seymour at the Peter MacCallum Cancer Centre.

"We are pleased with the advancement of our JAK2 inhibitor into a Phase 1/2 clinical trial in Australia as it exemplifies the expansion of our company's global development strategy," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "SB1518's strengths are in its exciting anti-proliferative and anti-tumor activity, as demonstrated by a range of in vitro and in vivo models, as well as its excellent tolerability. We believe this compound may eventually provide oncologists with a much needed and improved option to treat patients suffering from CIMF."

CIMF is a serious progressive and chronic condition whereby scar tissue develops in the bone marrow, resulting in a reduced ability to produce sufficient blood cells. Consequently, more blood cells are made in other organs, such as the liver and spleen which are not as efficient at blood cell production as the bone marrow. CIMF is characterized by an enlarged spleen and progressive anaemia. Current therapies for CIMF are mostly palliative in nature and survival rates can be short. While the actual cause of the disease is unknown, the JAK2 gene has been implicated i
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
2. S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
3. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
4. MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
5. Anpath Group, Inc. Advances Relationship With the Washington Metropolitan Area Transit Authority (Metro)
6. Despite Advances in the Accuracy of CT Colonography in Detecting Polyps, Digestive Health Experts Urge Patients to Consider Risks and Realities
7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
8. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
9. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
10. Two New Alzheimers Disease Studies Show Advances Against Different Treatment Targets
11. Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Ill. , Aug. 28, 2015 ... Companies, Inc. (Nasdaq: PDCO ), is now ... previously announced acquisition of Patterson Medical by Madison ... will retain its name for a transition period ... of rehabilitation and sports medicine products.  With the ...
(Date:8/28/2015)... Aug. 28, 2015 Research ... of the "Investigation Report on China,s Ranibizumab Market, ... by Novartis, ranibizumab was approved by CFDA to treat ... only Lucentis, a product of Novartis, is available in ... first self- developed drug for the treatment of wet ...
(Date:8/28/2015)...  Perrigo Company plc ("Perrigo") (NYSE: PRGO ; ... of leading OTC brands from GSK in an all ... a clear demonstration of Perrigo,s unique ability to maximize ... spanning 36 countries.  Perrigo Chairman, President ... are excited to complete this transaction, which clearly demonstrates ...
Breaking Medicine Technology:Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4
... Company (Nasdaq: PRGO ; TASE) today announced ... substantially all of the assets of CanAm Care, a ... approximately $36 million in cash. The acquisition is expected ... The assets acquired from CanAm Care include: ...
... SHENZHEN, China, Jan. 9, 2012 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International ... and marketer of medical devices worldwide, today announced updates on ... domestic and international markets in 2012. N ... 2011, Mindray released 13 new products, exceeding its product development ...
Cached Medicine Technology:Perrigo Acquires Assets of CanAm Care for $36 Million 2Perrigo Acquires Assets of CanAm Care for $36 Million 3Mindray Medical Exceeds 2011 Product Development Targets and Announces Strong 2012 Pipeline 2Mindray Medical Exceeds 2011 Product Development Targets and Announces Strong 2012 Pipeline 3Mindray Medical Exceeds 2011 Product Development Targets and Announces Strong 2012 Pipeline 4
(Date:8/28/2015)... ... August 28, 2015 , ... The Nashville Business ... veterans leading in business. Mr. Troy Mizell, Chairman of the Board at ... Business Journal's 2015 Veterans Awards will recognize Nashville military veterans who, through their ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Quatela Center for ... is the first and only nonsurgical product approved by the Food and Drug Administration ... Quatela and Dr. William Koenig are among the premier cosmetic surgeons ...
(Date:8/28/2015)... ... August 28, 2015 , ... Healthpointe clinics throughout Southern ... sea diving. The act of recreational diving exposes the body to extreme ... is vital that all recreational and professional divers undergo regular comprehensive scuba physicals. ...
(Date:8/28/2015)... ... August 28, 2015 , ... United Benefit Advisors ... TJS Insurance Group as its newest Partner Firm. Founded in 1924 and headquartered ... them focused on their goals. Within the past 10 years, TJS Insurance Group ...
(Date:8/28/2015)... Abilene, Texas (PRWEB) , ... August 28, 2015 , ... ... penned a new publication and pleads for swift actions to be taken in ... of unnatural disasters. , Yisrayl says scientists have yet to understand fully the ...
Breaking Medicine News(10 mins):Health News:MyGenetx Board Member Receives Veterans Award 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3Health News:Healthpointe Now Offering Scuba Physicals 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 3Health News:Wake Up and Smell the Sick Atmosphere Says Yisrayl Hawkins in New Article This Week 2
... PICK: Connexins: providing protection to cells destroyed in type ... lifelong disease characterized by high levels of sugar (glucose) ... immune system attacking and destroying the cells in their ... glucose levels. Surprisingly, little is known about the mechanisms ...
... Goodwin HealthDay Reporter , SUNDAY, Nov. 6 ... fresheners may evoke the holiday season for some. For ... runny, itchy noses and sneezing to asthma attacks. ... risen, so have complaints from their patients about reactions ...
... for the first time, they show significant decreases in crime, ... Researchers assessed more than 200 at-risk boys annually from ... crime, tobacco, alcohol, and marijuana use changed over time. While ... behavior, they had not isolated the additional effects of fatherhood. ...
... cells know what cell types to become? Why do cells ... develop into cancer cells? These are some of the questions ... research has a very strong position internationally and one of ... of Copenhagen. She has just received an ERC Starting Grant ...
... School of Medicine is honored to announce gifts to ... Research Foundation Professorship in Integrative Oncology. This professorship will ... as national leaders in teaching, research, and patient care ... gifts from The Parker Foundation and Helen Moss Cancer ...
... published research shows that more patients with end-stage ... hemodialysis as their initial kidney replacement therapy over ... the study now available in Arthritis Care ... College of Rheumatology (ACR), also found that African ...
Cached Medicine News:Health News:JCI online early table of contents: Nov. 7, 2011 2Health News:JCI online early table of contents: Nov. 7, 2011 3Health News:JCI online early table of contents: Nov. 7, 2011 4Health News:JCI online early table of contents: Nov. 7, 2011 5Health News:JCI online early table of contents: Nov. 7, 2011 6Health News:Air Fresheners, Scented Candles May Spur Allergic Reactions 2Health News:Air Fresheners, Scented Candles May Spur Allergic Reactions 3Health News:Fatherhood can help change a man's bad habits 2Health News:Research in cellular memory 2Health News:Pioneering professorship will teach innovative, patient-centered approach to cancer 2Health News:Pioneering professorship will teach innovative, patient-centered approach to cancer 3Health News:Most lupus nephritis patients with end-stage renal disease opt for hemodialysis therapy 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: